Lung cancer is the top cause of cancer death and the third most common cancer type in the United States, according to the National Cancer Institute. With an estimated 234,580 new cases of lung and bronchus cancer to be diagnosed in 2024 alone, this cancer will almost certainly affect a portion of your patients. Test your knowledge of this disease here.
References
- Lee CS, Milone M, Seetharamu N. Osimertinib in EGFR-mutated lung cancer: a review of the existing and emerging clinical data. Onco Targets Ther. 2021;14:4579-4597.
- Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339-346.
- Yin Q, Wu L, Han L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975.
- Du X, Shao Y, Qin HF, et al. ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer. 2018;9:423-430.
- Lin G, Yao Z, Kang K, et al. Efficacy and toxicity profile of first-line treatment for extensive-stage small cell lung cancer: a Bayesian network meta-analysis. Cancer Med. 2023;12:10230-10242.